Abstract
Medications currently approved by the US Food and Drug Administration (FDA) for obesity treatment most be considered in adults with a body mass index (BMI) of at least 30 kg/m2 or BMI of ≥27 plus at least one weight-related comorbidity, such as hypertension or type 2 diabetes [1] (Table 6.1). FDA approval implies that the drug must induce statistically significant weight loss of at least 5 % at 1 year when compared with placebo, and at least 35 % of patients must achieve at least a 5 % weight loss and show improvement in metabolic biomarkers. The drug must also be safe for use in the intended population [2].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Yanovski S, Yanovski J. Long-term drug treatment for obesity, a systematic and clinical review. JAMA. 2014;311:74–86.
Gnacinska M, Malgorzewicz S, Stojek M, Lysiak-Szydlowska W, Sworczak K. Role of adipokines in complications related to obesity: a review. Adv Med Sci. 2009;54:150–7.
Colon-Gonzalez F, Kim G, Lin J, Valentino M, Waldam S. Obesity pharmacotherapy: what is next. Mol Aspects Med. 2013;34:71–83.
Double-blind, multi-center, randomized study to assess the efficacy and safety of velneperit (S-2367) and orlistat administered individually or combined with a reduced calorie diet in obese subjects. https://clinicaltrials.gov/ct2/show/NCT01126970. Accessed 17 Mar 2015.
Safety study of the inhibition of agouti-related protein (AgRP) for the management of obesity and weight loss. https://clinicaltrials.gov/ct2/show/NCT00779519. Accessed 17 Mar 2015.
Dodds CM, O’Neill B, Beaver J, Makwana A, Bani M, Merlo-Pich E, et al. Effects of the D3 antagonist GSK598809 on brain responses to rewarding food images in overweight and obese binge eaters. Appetite. 2012;59:27–33.
Malmlöf K, Zaragoza F, Golozoubova V, Refsgaard HH, Cremers T, Raun K, et al. Influence of a selective histamine H3 receptor antagonist on hypothalamic neural activity, food intake and body weight. Int J Obes (Lond). 2005;29:1402–12.
Santoprete A, Capitò E, Carrington PE, Pocai A, Finotto M, Langella A, et al. DPP-IV-resistant, long-acting oxyntomodulin derivatives. J Pept Sci. 2011;17:270–80.
Koda J, Weyer C, Smith S, Ravussin E, Mitchell J. Enhanced weight loss following pramlintide/metreleptin combination treatment in obese subjects: clinical evidence for restoration of leptin responsiveness by amylin agonism. 44th annual meeting of the European Association for the study of diabetes. 7 Sep 2008: Abstr. 83.
Kopelman P, Groot Gde H, Rissanen A, Rossner S, Toubro S, Palmer R, et al. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver Spring). 2010;18:108–15.
Álvarez-Castro P, Pena L, Cordido F. Ghrelin in obesity, physiological and pharmacological considerations. Mini Rev Med Chem. 2013;13:541–52.
Kim G, Lin J, Blomain E, Waldman S. Anti-obesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther. 2014;95:53–66.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
González, H. (2016). Pharmacotherapy. In: Managing Patients with Obesity. Adis, Cham. https://doi.org/10.1007/978-3-319-12331-8_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-12331-8_6
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-12330-1
Online ISBN: 978-3-319-12331-8
eBook Packages: MedicineMedicine (R0)